ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > And there you have it.

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Aug 23, 2023 10:57pm

134 Views

Post# 35603081

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:And there you have it.

Agreed. The system is a joke, and the average joe is the butt of it.

Most who in fall into the category that would benefit from stock price manipulation would argue that they got into said category by working harder/taking better advantage of the system than the average joe. And maybe they have a point. Sort of.

But I would argue that the original design of the system was to allow the average joe to at least have the opportunity to prosper from this type of speculation.

But I digress. Long story short, the rich get richer. IMO.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario